Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide
| Foreign code | F170009182 |
|---|---|
| File No. | AF12-05WO |
| Posted date | Sep 12, 2017 |
| Country | United States of America |
| Application number | 201113579529 |
| Gazette No. | 20120322135 |
| Gazette No. | 9365637 |
| Date of filing | Feb 21, 2011 |
| Gazette Date | Dec 20, 2012 |
| Gazette Date | Jun 14, 2016 |
| International application number | JP2011053752 |
| International publication number | WO2011102517 |
| Date of international filing | Feb 21, 2011 |
| Date of international publication | Aug 25, 2011 |
| Priority data |
|
| Title | Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide |
| Abstract |
(US9365637) The present invention provides: a novel antiviral agent containing a human antibody κ light chain, a novel human abzyme containing a human antibody κ light chain; a polynucleotide, a vector, and a transformant, encoding a human antibody κ light chain of the above; a primer set for effectively obtaining a human antibody κ light chain having a function as an antiviral agent or abzyme; and a method for producing a polynucleotide and a method for producing a polypeptide, each of which method utilizes the primer set. |
| Scope of claims |
[claim1] 1. A human abzyme comprising one of the following (a) through (f): (a) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 26, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 24; (b) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 14, and a constant domain with an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 1; (c) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 50, and a constant domain with an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 48; (d) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 35, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 33; (e) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 54, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 52; or (f) a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 22, and a constant domain with an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 20. [claim2] 2. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti rhabdovirus activity, and anti influenza virus activity; and the variable domain consists of SEQ ID NO: 26, the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 20. [claim3] 3. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti rhabdovirus activity, anti influenza virus activity, and cytotoxicity against cancer cells; and the variable domain consists SEQ ID NO: 14, the constant domain has an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 1. [claim4] 4. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti influenza virus activity and nucleolytic activity; and the variable domain consists of SEQ ID NO: 50, the constant domain has an Ala in the position corresponding to Cys220 in the amino acid sequence shown in SEQ ID NO: 48. [claim5] 5. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti influenza virus activity; and the variable domain consists of SEQ ID NO: 35, the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 33. [claim6] 6. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti influenza virus activity; and the variable domain consists of SEQ ID NO: 54, the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 52. [claim7] 7. The human abzyme as set forth in claim 1, wherein: the human abzyme has an anti rhabdovirus activity; and the variable domain consists of SEQ ID NO: 22, the constant domain has an Ala in the position corresponding to Cys219 in the amino acid sequence shown in SEQ ID NO: 20. [claim8] 8. A method for treating a patient of a rhabdovirus infectious disease by administering a human abzyme comprising a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 26, 14, 30, or 22 to the patient, wherein the administering does not comprise administering a human antibody heavy chain. [claim9] 9. A method for treating a patient of an influenza virus infectious disease by administering a human abzyme comprising a human antibody kappa (kappa ) light chain with a variable domain consisting of SEQ ID NO: 26, 14, 50, 35 or 54 to the patient. |
|
|
| IPC(International Patent Classification) |
|
| Reference ( R and D project ) | CREST Establishment of Innovative Manufacturing Technology Based on Nanoscience AREA |
※
Please contact us by E-mail or facsimile if you have any interests on this patent.
Contact Information for " Antiviral agent, abzyme, primer set, method for producing polynucleotide, and method for producing polypeptide "
- Japan Science and Technology Agency Department of Intellectual Property Management
- URL: http://www.jst.go.jp/chizai/
-
E-mail:
- Address: 5-3, Yonbancho, Chiyoda-ku, Tokyo, Japan , 102-8666
- Fax: 81-3-5214-8476
※ It is possible to retrieve in J-STORE by the same key word. → Retrieval result of J-STORE
